Last 7 days
1.8%
Last 30 days
-0.9%
Last 90 days
-3.3%
Trailing 12 Months
26.8%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 127.1B | 26.3B | 0.79% | 2.78% | 19.4 | 4.83 | 1.32% | 11.18% |
GILD | 99.8B | 27.3B | -4.19% | 39.66% | 21.72 | 3.66 | -0.09% | -26.23% |
MRNA | 58.1B | 19.3B | -4.61% | -16.03% | 6.95 | 3.02 | 4.29% | -31.47% |
BIIB | 39.0B | 10.2B | -0.92% | 26.77% | 12.8 | 3.83 | -7.36% | 95.80% |
MID-CAP | ||||||||
NBIX | 9.4B | 1.5B | -5.59% | 3.19% | 60.62 | 6.29 | 31.34% | 72.43% |
DNLI | 3.1B | 108.5M | -21.66% | -32.82% | -9.55 | 28.71 | 122.90% | -12.19% |
BBIO | 2.2B | 107.9M | 21.83% | 38.60% | -4.63 | 20.79 | 54.84% | 17.36% |
BEAM | 2.2B | 60.9M | -25.55% | -48.21% | -7.49 | 35.56 | 17.51% | 22.00% |
SMALL-CAP | ||||||||
RCUS | 1.3B | 112.0M | -7.70% | -49.25% | -4.81 | 11.47 | -70.76% | -603.77% |
REPL | 1.1B | 7.0M | -17.00% | 22.02% | -7.14 | 159.78 | 131.81% | -45.39% |
FATE | 524.4M | 96.3M | -14.58% | -86.07% | -1.86 | 5.45 | 72.44% | -32.79% |
NVAX | 519.7M | 2.0B | -33.63% | -92.58% | -0.79 | 0.26 | 72.89% | 62.27% |
SGMO | 276.9M | 111.3M | -42.96% | -71.96% | -1.44 | 2.49 | 0.54% | -7.86% |
VXRT | 101.6M | 107.0K | -17.23% | -85.52% | -0.94 | 949.93 | -88.00% | -52.91% |
IBIO | 26.0M | - | 40.00% | -84.44% | -0.32 | 3.21 | 0.51% | -185.61% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -1.8% | 10,173 | 10,363 | 10,634 | 10,820 | 10,982 |
S&GA Expenses | -6.1% | 2,404 | 2,559 | 2,650 | 2,714 | 2,674 |
Costs and Expenses | -1.9% | 6,582 | 6,707 | 8,057 | 8,931 | 9,237 |
EBITDA | 4.1% | 4,357 | 4,184 | 3,123 | 2,407 | - |
EBITDA Margin | 6.1% | 0.43* | 0.40* | 0.29* | 0.22* | - |
Earnings Before Taxes | 5.9% | 3,592 | 3,393 | 2,313 | 1,626 | 1,745 |
EBT Margin | 7.8% | 0.35* | 0.33* | 0.22* | 0.15* | - |
Interest Expenses | -4.5% | 247 | 258 | 265 | 255 | 254 |
Net Income | 6.4% | 3,047 | 2,865 | 2,059 | 1,450 | 1,556 |
Net Income Margin | 8.3% | 0.30* | 0.28* | 0.19* | 0.13* | - |
Free Cahsflow | -47.8% | 1,144 | 2,192 | 2,354 | 2,809 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -1.2% | 24,554 | 24,854 | 25,081 | 23,614 | 23,877 |
Current Assets | 0.3% | 9,791 | 9,766 | 9,741 | 7,916 | 7,857 |
Cash Equivalents | -7.0% | 3,419 | 3,676 | 2,647 | 1,749 | 2,261 |
Inventory | -2.2% | 1,344 | 1,375 | 1,294 | 1,215 | 1,352 |
Net PPE | 1.0% | 3,299 | 3,266 | 3,355 | 3,373 | 3,416 |
Goodwill | 0.1% | 5,749 | 5,741 | 5,750 | 5,758 | 5,761 |
Liabilities | -7.6% | 11,166 | 12,087 | 13,218 | 12,394 | 12,918 |
Current Liabilities | -16.6% | 3,273 | 3,926 | 5,018 | 3,947 | 4,298 |
Long Term Debt | 0.0% | 6,281 | 6,279 | 6,277 | 6,276 | 6,274 |
Shareholder's Equity | 4.9% | 13,398 | 12,776 | 11,863 | 11,221 | 10,896 |
Retained Earnings | 3.5% | 16,467 | 15,916 | 14,960 | 14,216 | 13,912 |
Additional Paid-In Capital | Infinity% | 73.00 | - | - | 119 | 68.00 |
Accumulated Depreciation | - | 2,007 | - | - | - | - |
Shares Outstanding | -1.0% | 144 | 146 | 147 | - | - |
Minority Interest | -9.2% | -9.50 | -8.70 | -9.10 | -21.60 | 64.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -42.3% | 1,384 | 2,398 | 2,542 | 3,033 | 3,640 |
Share Based Compensation | 9311.1% | 254 | 3.00 | 11.00 | 13.00 | 239 |
Cashflow From Investing | -1.8% | 1,577 | 1,605 | -300 | -1,147 | -563 |
Cashflow From Financing | -1.0% | -1,747 | -1,730 | -1,224 | -1,317 | -2,086 |
Buy Backs | 0% | 750 | 750 | 1,250 | 1,200 | 1,800 |
87.3%
55.8%
15%
Y-axis is the maximum loss one would have experienced if Biogen was unfortunately bought at previous high price.
5.2%
2.0%
0.8%
-0.7%
FIve years rolling returns for Biogen.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 14.22 | 208,339 | 1,343,340 | 0.04% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -4.7 | -505,418 | 43,161,600 | 0.05% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 4.87 | 144,000 | 1,789,000 | 0.01% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | reduced | -2.03 | 4,967 | 279,967 | 0.02% |
2023-03-03 | TIAA, FSB | reduced | -14.89 | -148,012 | 1,115,990 | -% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | new | - | 7,200 | 7,200 | -% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 1,961,700 | 1,961,700 | 0.02% |
2023-03-01 | Regal Investment Advisors LLC | reduced | -2.18 | 6,318 | 435,318 | 0.04% |
2023-02-28 | Voya Investment Management LLC | added | 2.58 | 1,972,790 | 32,853,800 | 0.05% |
2023-02-24 | SRS Capital Advisors, Inc. | unchanged | - | 385 | 1,385 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 8.32% | 11,976,623 | SC 13G/A | |
Feb 09, 2023 | primecap management co/ca/ | 10.9% | 15,700,576 | SC 13G/A | |
Jan 24, 2023 | blackrock inc. | 9.9% | 14,260,137 | SC 13G/A | |
Mar 07, 2022 | blackrock inc. | 9.4% | 13,736,954 | SC 13G/A | |
Feb 10, 2022 | primecap management co/ca/ | 10.73% | 15,757,405 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 7.85% | 11,537,299 | SC 13G/A | |
Feb 08, 2022 | blackrock inc. | 9.4% | 13,736,954 | SC 13G | |
Feb 12, 2021 | primecap management co/ca/ | 10.28% | 15,822,066 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 7.73% | 11,896,510 | SC 13G/A | |
Jan 29, 2021 | blackrock inc. | 8.7% | 13,419,601 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 152.60 -43.49% | 191.69 -29.01% | 289.90 7.36% | 365.74 35.44% | 420.23 55.62% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 09, 2023 | 8-K | Current Report | |
Mar 06, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 4 | Insider Trading | |
Feb 22, 2023 | 4 | Insider Trading | |
Feb 15, 2023 | 10-K | Annual Report |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-02 | Singhal Priya | sold (taxes) | -184,631 | 268 | -687 | head of development |
2023-03-02 | Singhal Priya | acquired | - | - | 297 | head of development |
2023-02-17 | Singhal Priya | sold (taxes) | -42,035 | 278 | -151 | head of development |
2023-02-17 | Kramer Robin | acquired | - | - | 512 | chief accounting officer |
2023-02-17 | ALEXANDER SUSAN H | sold (taxes) | -258,615 | 278 | -929 | evp chief legal off & corp sec |
2023-02-17 | Singhal Priya | acquired | - | - | 460 | head of development |
2023-02-17 | Gregory Ginger | sold (taxes) | -241,355 | 278 | -867 | evp, human resources |
2023-02-17 | Izzar Rachid | acquired | - | - | 767 | head of global product strat. |
2023-02-17 | MCDONNELL MICHAEL R | acquired | - | - | 2,561 | evp, chief financial officer |
2023-02-17 | MCDONNELL MICHAEL R | sold (taxes) | -364,678 | 278 | -1,310 | evp, chief financial officer |
Consolidated Statements of Income - USD ($) shares in Thousands, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenues | $ 10,173.4 | $ 10,981.7 | $ 13,444.6 |
Cost and expense: | |||
Cost of sales, excluding amortization and impairment of acquired intangible assets | 2,278.3 | 2,109.7 | 1,805.2 |
Research and development | 2,231.1 | 2,501.2 | 3,990.9 |
Selling, general and administrative | 2,403.6 | 2,674.3 | 2,504.5 |
Amortization and impairment of acquired intangible assets | 365.9 | 881.3 | 464.8 |
Collaboration profit (loss) sharing | (7.4) | 7.2 | 232.9 |
(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations | 0.0 | 0.0 | (92.5) |
(Gain) loss on fair value remeasurement of contingent consideration | (209.1) | (50.7) | (86.3) |
Acquired in-process research and development | 0.0 | 18.0 | 75.0 |
Restructuring charges | 131.1 | 0.0 | 0.0 |
Gain on sale of building | (503.7) | 0.0 | 0.0 |
Other (income) expense, net | (108.2) | 1,095.5 | (497.4) |
Total cost and expense | 6,581.6 | 9,236.5 | 8,397.1 |
Income before income tax expense and equity in loss of investee, net of tax | 3,591.8 | 1,745.2 | 5,047.5 |
Income tax (benefit) expense | 632.8 | 52.5 | 992.3 |
Equity in (income) loss of investee, net of tax | (2.6) | (34.9) | (5.3) |
Net income | 2,961.6 | 1,727.6 | 4,060.5 |
Net income (loss) attributable to noncontrolling interests, net of tax | (85.3) | 171.5 | 59.9 |
Net income attributable to Biogen Inc. | $ 3,046.9 | $ 1,556.1 | $ 4,000.6 |
Net income per share: | |||
Basic earnings per share attributable to Biogen Inc. (in dollars per share) | $ 20.96 | $ 10.44 | $ 24.86 |
Diluted earnings per share attributable to Biogen Inc. (in dollars per share) | $ 20.87 | $ 10.40 | $ 24.80 |
Weighted-average shares used in calculating: | |||
Weighted average number of common shares outstanding (in shares) | 145,300 | 149,100 | 160,900 |
Diluted earnings per share attributable to Biogen Inc. (in shares) | 146,000 | 149,600 | 161,300 |
Product, net | |||
Revenues | $ 7,987.8 | $ 8,846.9 | $ 10,692.2 |
Revenue from anti-CD20 therapeutic programs | |||
Revenues | 1,700.5 | 1,658.5 | 1,977.8 |
Other | |||
Revenues | $ 485.1 | $ 476.3 | $ 774.6 |
Consolidated Balance Sheets - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 3,419.3 | $ 2,261.4 |
Marketable securities | 1,473.5 | 1,541.1 |
Accounts receivable, net | 1,705.0 | 1,549.4 |
Due from anti-CD20 therapeutic programs | 431.4 | 412.3 |
Inventory | 1,344.4 | 1,351.5 |
Other current assets | 1,417.6 | 740.8 |
Total current assets | 9,791.2 | 7,856.5 |
Marketable securities | 705.7 | 892.0 |
Property, plant and equipment, net | 3,298.6 | 3,416.4 |
Operating lease assets | 403.9 | 375.4 |
Intangible assets, net | 1,850.1 | 2,221.3 |
Goodwill | 5,749.0 | 5,761.1 |
Deferred tax asset | 1,226.4 | 1,415.1 |
Investments and other assets | 1,529.2 | 1,939.5 |
Total assets | 24,554.1 | 23,877.3 |
Current liabilities: | ||
Current portion of notes payable | 0.0 | 999.1 |
Taxes payable | 259.9 | 174.7 |
Accounts payable | 491.5 | 589.2 |
Accrued expense and other | 2,521.4 | 2,535.2 |
Total current liabilities | 3,272.8 | 4,298.2 |
Notes payable | 6,281.0 | 6,274.0 |
Deferred tax liability | 334.7 | 694.5 |
Long-term operating lease liabilities | 333.0 | 330.4 |
Other long-term liabilities | 944.2 | 1,320.5 |
Total liabilities | 11,165.7 | 12,917.6 |
Commitments, contingencies and guarantees (Notes 22 and 23) | ||
Biogen Inc. shareholders’ equity | ||
Preferred stock, par value $0.001 per share | 0.0 | 0.0 |
Common stock, par value $0.0005 per share | 0.1 | 0.1 |
Additional paid-in capital | 73.3 | 68.2 |
Accumulated other comprehensive loss | (164.9) | (106.7) |
Retained earnings | 16,466.5 | 13,911.7 |
Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively | (2,977.1) | (2,977.1) |
Total Biogen Inc. shareholders’ equity | 13,397.9 | 10,896.2 |
Noncontrolling interests | (9.5) | 63.5 |
Total equity | 13,388.4 | 10,959.7 |
Total liabilities and equity | $ 24,554.1 | $ 23,877.3 |